Get the Stockscreener App
1.63
2.39%
-0.0399
Intercure Ltd stock is traded at $1.63, with a volume of 5,681.
It is down -2.39% in the last 24 hours and up +2.52% over the past month.
Intercure Ltd is engaged in the research, cultivation, production, and distribution of pharma-grade cannabis-based products. The products are distributed to hospitals, pharmacies, research, and government organizations. The company has two segments namely: Cannabis segment and Biomed segment, out of which it derives maximum revenue from Cannabis segment.
See More
Previous Close:
$1.6699
Open:
$1.61
24h Volume:
5,681
Relative Volume:
0.15
Market Cap:
$74.60M
Revenue:
$118.18M
Net Income/Loss:
$5.99M
P/E Ratio:
12.36
EPS:
0.1319
Net Cash Flow:
$-12.91M
1W Performance:
-6.32%
1M Performance:
+2.52%
6M Performance:
-25.57%
1Y Performance:
+38.14%
1-Day Range:
$1.6011
$1.68
1-Week Range:
$1.6011
$1.75
52-Week Range:
$1.17
$3.72
Intercure Ltd Stock (INCR) Company Profile
Compare INCR with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
INCR
Intercure Ltd
|
1.63 | 74.60M | 118.18M | 5.99M | -12.91M | 0.1319 |
|
ZTS
Zoetis Inc
|
170.90 | 77.10B | 9.15B | 2.43B | 2.31B | 5.32 |
|
HLN
Haleon Plc Adr
|
9.47 | 42.82B | 14.26B | 1.55B | 0 | 0.3383 |
|
TAK
Takeda Pharmaceutical Co Adr
|
13.39 | 42.45B | 30.27B | 1.93B | 3.45B | 0.6044 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
17.73 | 20.09B | 16.77B | -959.00M | 1.37B | -0.85 |
|
NBIX
Neurocrine Biosciences Inc
|
151.82 | 15.37B | 2.24B | 385.90M | 440.10M | 3.73 |
Intercure Ltd Stock (INCR) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| May-18-22 | Upgrade | Canaccord Genuity | Speculative Buy → Buy |
Intercure Ltd Stock (INCR) Latest News
InterCure Ltd. (NASDAQ:INCR) Short Interest Update - MarketBeat
Jane Street Group LLC Acquires New Stake in InterCure Ltd. (NASDAQ:INCR) - Defense World
InterCure (NASDAQ:INCR) Trading Up 3.7%What's Next? - MarketBeat
InterCure (NASDAQ:INCR) Trading Up 3.7% – Should You Buy? - Defense World
Cannabis co InterCure raising NIS 66m for Nir Oz facility - Globes
InterCure secures $18.2M for post-war recovery By Investing.com - Investing.com Australia
InterCure secures $18.2M for post-war recovery - Investing.com
InterCure Secures Major Funding to Boost Growth - TipRanks
InterCure has Secured Funding of NIS 66M to support the recovery of Nir Oz Facility - Nasdaq
Reviewing InterCure (NASDAQ:INCR) & NeuroBo Pharmaceuticals (NASDAQ:NRBO) - Defense World
InterCure Ltd. (NASDAQ:INCR) Sees Significant Drop in Short Interest - MarketBeat
InterCure Ltd. (NASDAQ:INCR) Sees Large Decline in Short Interest - MarketBeat
Synbiotic's CAGR Forecast at 80%, ECS Botanics to Expand Footprint in Germany, & More from Intercure - Business of Cannabis -
Are Investors Missing The Forest? 35% Stock Drop Masks The International Potential Of This Weed Company - Benzinga
Weekly Roundup on the Cannabis Sector & Psychedelic Sector - Market Exclusive
InterCure Ltd. (NASDAQ:INCR) Sees Significant Increase in Short Interest - MarketBeat
Top Seller Of Pharmaceutical Cannabis Outside US Grew By Double-Digits, Focuses On Germany - Benzinga
InterCure nears break even in first half of 2024, despite ongoing Israel-Hamas war - Green Market Report
InterCure Announces First Half of 2024 Results: Revenue of NIS 126 million and Adjusted EBITDA of NIS 21 million - GlobeNewswire
InterCure Ltd. Reports Earnings Results for the Half Year Ended June 30, 2024 - Marketscreener.com
InterCure partners with Cookies to launch cannabis pharmacies in Germany By Investing.com - Investing.com Australia
InterCure partners with Cookies to launch cannabis pharmacies in Germany - Investing.com
InterCure Announces Expansion of its Strategic partnership with Cookies to Germany - Business Wire
InterCure (NASDAQ:INCR) Stock Price Up 0.5% - MarketBeat
Tidal Investments LLC Invests $883,000 in InterCure Ltd. (NASDAQ:INCR) - American Banking and Market News
Cannabis News: Majority of Americans Want Rescheduling or Legalization; European Market Growth Could be Game-Changer; Spotlight on InterCure - Market Research Record
Support for Regulatory Changes Surrounding Cannabis Remains Strong in the US, Companies Like InterCure Could Also Benefit From Growth in Europe - Markets Herald
IM Cannabis Merger Scrapped, Cel AI Gets a New CEO, & More from Intercure - Business of Cannabis -
Asset-Light Expansion Into $8B German Market Adds Potential To This Cannabis Stock On NASDAQ - Benzinga
Analyst: Israel’s InterCure paving path to big gains - Green Market Report
InterCure to Participate in Canaccord Genuity’s 8th Annual Global Cannabis Conference - Yahoo Finance
InterCure Announces FY2023 Results: Revenue of NIS 356 million and Adjusted EBITDA of NIS 61 million - Business Wire
InterCure: Bargain Israel Cannabis Play (NASDAQ:INCR) - Seeking Alpha
InterCure Announces Preliminary Estimated 2023 Revenue of NIS 351 million and EBITDA of over NIS 50 million - Yahoo Finance
symbol__ Stock Quote Price and Forecast - CNN
InterCure Congratulates Germany on Cannabis Reform, Expanding its Global Footprint - Business Wire
InterCure Provides Update Regarding Nir Oz Facility in Israel - Cannabis Business Times
InterCure Provides an Update Regarding Nir Oz Facility - GlobeNewswire
InterCure Signs Definitive Agreement to Acquire Leon Cannabis Pharmacy Chain - GlobeNewswire
Israeli Cannabis Firms Navigate Challenges Amid Hamas Conflict, Cellular Goods Signs New Joint Venture, & More from SEED Innovations - Business of Cannabis -
InterCure Provides an Update Regarding the Security Situation in Israel - Financial Post
Israeli Cannabis Adjusts to War - Green Market Report
Celadon Announces New £1.2m Supply Deal, Intercure Continues Record Run, & Chill Brands Launches Products in UK - Business of Cannabis -
InterCure Announces Record Revenues First Half of 2023 with over 14% growth YOY - GlobeNewswire
InterCure Decides to Leave Toronto Stock Exchange - Green Market Report
InterCure Ltd. Announces Proposed Voluntary Delisting from - GlobeNewswire
Cookies launches flagship store in Austria with InterCure - Business of Cannabis -
Intercure Counter-Sued By Better, Cantourage Sees Stock Jump 30%, & Tikun Olam Cannbit To Be Acquired - Business of Cannabis -
InterCure Announces Record Breaking First Quarter Revenues with 22% growth YOY - GlobeNewswire
InterCure to distribute Mike Tyson’s cannabis internationally - Mugglehead
InterCure Ltd. Partners with TYSON 2.0 in Israel, Australia, United Kingdom, Germany and Other EU Countries - GlobeNewswire
Intercure Ltd Stock (INCR) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.19%
0.06%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):